- Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3💵 Oak Hill Bio’s SPAC merger: The Angelman syndrome biotech will merge with RA Capital’s blank-check company, called Research Alliance Corporation III, and get about ...Endpoints · 44m ago↗ source
- FDA staff say Replimune's melanoma trial failed to prove RP1 worksFDA staff threw cold water on Replimune’s advanced melanoma drug ahead of a critical meeting with agency advisors, writing that the pivotal study design failed to prove its drug actually works. T…Endpoints · 57m ago↗ source
- The future of gray-market peptidesTwo days’ worth of debate among FDA advisory committee members and agency staff over whether compounding pharmacies should be able to make seven different peptides left me with some big ...